News Archive

TriFusion Devices from Texas A&M University emerged as the top startup company in the Rice Business Plan Competition (RBPC) tonight at Rice University’s Jones Graduate School of Business. The annual event is the world’s richest and largest student startup competition.

Selected by 275 judges from the investment sector as representing the best investment opportunity and taking home nearly $400,000 in cash and prizes, TriFusion Devices bested 41 other competitors hailing from some of the world’s top universities. TriFusion Devices offers breakthrough 3-D printed products and services aimed at revolutionizing the health care and sports-equipment industries in powerful and profitable ways.

Significant new prizes this year and the teams that won them include the following:

* $25,000 Rice Brown School of Engineering Tech Innovation Prize – Leuko, Massachusetts Institute of Technology.

* $100,000, Cisco Internet of Everything Innovation Challenge Prize – Neopenda, Columbia University.

Join our monthly funding briefing to learn details about TEDCO’s 8 funding programs. Get insights on:

• navigating through TEDCO’s funding resources,
• the application process and deadlines,
• what the reviewers are looking for,
• how your company can take advantage of TEDCO supporting programs

More than 700 leaders from life science companies, academic institutions, nonprofit organizations, investment funds and government entities across Maryland, Virginia and Washington, D.C. (MD-VA-DC) will convene today and tomorrow for the second annual Regional BioTech Forum. The event will showcase the region’s biotechnology accomplishments and its commitment to advancing cutting-edge research in the MD-VA-DC corridor. Notable speakers will include: Dr. Francis Collins, Director, National Institutes of Health; Maryland Governor Larry Hogan; Virginia Governor Terry McAuliffe; and Congressman John Delaney.

Illumina is committing $100 million over 10 years to a new venture capital firm whose investment priorities will be in line with the company’s vision.

Illumina said the new firm—to be called Illumina Ventures—will be managed independently of the sequencing giant. However, Illumina will be the majority limited partner in the firm’s first fund as a result of its commitment.

The Washington, D.C. mayor has called for a vote this year on statehood for the nation’s capital.

Speaking Friday at an event commemorating the district’s emancipation from slavery, D.C. Mayor Muriel Bowser said, “I propose we take another bold step toward democracy in the District of Columbia,” according to the Washington Post. “It’s going to require that we send a bold message to the Congress and the rest of the country, that we demand not only a vote in the House of Representatives. We demand two senators—the full rights of citizenship in this great nation.”

Each spring Johns Hopkins honors exceptional graduate students and postdoctoral fellows at the annual Young Investigators’ Day celebration. The day is meant to celebrate the achievement and hard work of not only the award winners, but of all Johns Hopkins’ research trainees. This year two BME PhD candidates and a BME MD PhD candidate were selected to receive distinguished awards. The awards, named after notable researchers, including many who were former faculty members or graduate students at The Johns Hopkins University, were granted in recognition of outstanding research

You probably know Steve Case best as the man responsible for America Online. But two decades later, Case is continuing the charge to help the new generation of technology and business leaders define the critical path of Internet and innovation to become much more useful to society.

Precision for Medicine, part of the Precision Medicine Group, announced today that it has executed a binding agreement to acquire ACT Oncology, the leading contract research organization (CRO) specializing exclusively in the field of oncology. ACT Oncology provides drug development services focused on the design and execution of clinical trials on behalf of innovative life sciences companies and not-for-profit patient organizations.

Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc’s Aricept® Tablets, 23mg.

Nearly 50 new medicines are projected to be launched each year by 2020, a new report from the IMS Institute for Healthcare Informatics says. As such, a number of new drug brands will be available on the market. The majority, unsurprisingly, will be designed to treat cancer.